Table 1.
Baseline characteristics and outcome in human study
| Variable | ASV Group (n = 9) |
PCV Group (n = 6) |
p Value |
|---|---|---|---|
| Age, yr, mean ±SD | 62.0 ± 18.5 | 62.5 ± 30.3 | 0.776 |
| ApacheⅡscores, mean ±SD | 17.0 ± 5.44 | 21 ± 8.46 | 0.524 |
| Gender, male/female (%) | 7/2(77.8/22.2) | 4/2(66.7/33.3) | 1 |
| Baseline Condition | |||
| IBW, kg, mean ±SD | 61.9 ± 6.23 | 57.2 ± 7.33 | 0.145 |
| PaO2/FiO2, mean ±SD | 153.6 ± 53.6 | 156.7 ± 32.8 | 1 |
| Static compliance, ml/cmH2O, mean ±SD | 28.0 ± 10.6 | 32.7 ± 10.5 | 0.529 |
| Pressure level, cmH2O, mean ±SD | 19.8 ± 2.79 | 17.3 ± 4.5 | 0.456 |
| PEEP level, cmH2O, mean ±SD | 14.8 ± 3.15 | 12.4 ± 0.9 | 0.066 |
| Minute volume, l/min, mean ±SD | 11.8 ± 2.52 | 10.7 ± 2.26 | 0.388 |
| Tidal volume/IBW, ml/kg, mean ±SD | 7.06 ± 1.2 | 7.61 ± 0.38 | 0.272 |
| Total respiratory rate, breaths/min, mean ±SD | 27.1 ± 7.5 | 24.0 ± 6.5 | 0.529 |
| Mean BP, mmHg, mean ±SD | 90.4 ± 16.9 | 84.5 ± 28.8 | 0.607 |
| Sedation +/−, (%) | 8/1(88.9/11.1) | 6/0(100/0) | 1 |
| Muscle relaxants +/−, (%) | 4/5(44.4/55.6) | 2/4(33.3/66.7) | 1 |
| Inotropic drug +/−, (%) | 1/8(11.1/88.9) | 3/3(50/50) | 0.235 |
| Main Outcome | |||
| Wean success / fail n. (%) | 5/4(55.6/44.4) | 2/4(33.3/66.7) | 0.608 |
| Ventilator-free days, median (IQR) | 7(4–9) | 8(4.5–17) | 0.473 |
| Days in ICU, median (IQR) | 15(12.5–16.5) | 13(5.5–21.5) | 0.314 |
| Days of hospitalization, median (IQR) | 29(19–55) | 15(11–43.5) | 0.174 |
| Alive/death n. (%) | 4/5(44.4/55.6) | 2/4(33.3/66.7) | 0.608 |
Values are expressed as mean (SD) unless indicated otherwise. ASV, adaptive support ventilation; PCV, pressure-control ventilation; APACHE II, acute physiology and chronic health evaluation II; IBW, ideal body weight; P/F, ratio of arterial partial oxygen pressure to inspiratory oxygen concentration; PEEP, positive end-expiratory pressure; mean BP, mean arterial blood pressure; IQR, interquartile range; ICU, intensive care unit. Sedative agents included midazolam and propofol. Muscle relaxants included Nimbex and Pavalon. Inotropic agents included dopamine, noradrenaline, and vasopressin. Data were compared using the Mann–Whitney U test or χ2 test.